Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98.65 SEK | +2.02% | +0.46% | -9.83% |
Apr. 24 | Transcript : AddLife AB, Q1 2024 Earnings Call, Apr 24, 2024 | |
Apr. 24 | AddLife AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 45.4 and 28.06 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.83% | 1.1B | C | ||
+1.51% | 42.75B | B | ||
+49.22% | 41.61B | A | ||
+8.57% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
-25.13% | 18.12B | B | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALIF B Stock
- Ratings AddLife AB